Your browser version may not work well with NCBI's Web applications. More information here...
Related Articles, Links
Click here to read Click here to read
Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing.

Kimpen JL.

Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands. j.kimpen@wkz.azu.nl

Respiratory syncytial virus (RSV) is the primary cause of hospitalization for acute respiratory tract illness in general and specifically for bronchiolitis in young children. The link between RSV bronchiolitis and reactive airway disease is not completely understood, even though RSV bronchiolitis is frequently followed by recurrent episodes of wheezing. Therapy with ribavirin does not appear to significantly reduce long-term respiratory outcome of RSV lower respiratory tract infection, and corticosteroid or bronchodilator therapy may possibly improve outcomes only on a short-term basis. No vaccine against RSV is yet available. It is not known whether prophylaxis with RSV intravenous immune globulin or palivizumab can reduce postbronchiolitic wheezing.

Publication Types:
PMID: 12119057 [PubMed - indexed for MEDLINE]

PMCID: PMC1866374